Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant plus chemotherapy and bevacizumab for second-line advanced colorectal cancer
ChiCTR2400081605Phase 2Not yet recruiting
- Sponsor
- 903rd Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fosaprepitant in colorectal adenocarcinoma (2 arms), sponsored by 903rd Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
fosaprepitant
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400081605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081605.